Oratec Interventions to float within three months
This article was originally published in Clinica
Oratec Interventions, a manufacturer of thermal-energy based arthroscopic and spinal products, intends to float within the next three months. The Menlo Park, California-based company has two commercially available products based on its technology which uses heat to shrink and repair damaged or stretched soft tissue. The company has filed a registration statement with the US Securities and Exchange Commission.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.